Life After Pfizer: MicuRx Forms JV To Develop Antibiotics In China
This article was originally published in PharmAsia News
Executive Summary
The JV with Shanghai Zhangjiang Biomedical Industry Venture Capital will fund the development and commercialization of MicuRx’s novel antibiotic MRX-I for the Chinese market.